Sponsored Links / Ads
 

Prostate Cancer

Prostate Cancer: Fewer Moderate and Serious Side Effects Reported with IMRT Than With Brachytherapy 
  Submitted By: Information, News and Press Releases

Printer Friendly Version

Source: Fox Chase Cancer Center (11-02-2006)

Patients Report Fewer Moderate and Serious Side Effects with IMRT Than With Brachytherapy for Treatment of Low-Risk Prostate Cancer

PHILADELPHIA -In one of the first studies to compare side effects of IMRT and permanent prostate brachytherapy (I-125) for treatment of low-risk prostate cancer, researchers say patients had fewer moderate and serious side effects when treated with IMRT. The study results were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

"Both treatments demonstrated excellent PSA outcomes (biochemical control) after treatment," said Thomas N. Eade, MBChB, a fellow in the department of radiation oncology at Fox Chase Cancer Center. "The patients who received IMRT tended to be older, but even with that factor, IMRT was better tolerated." PSA, or prostate specific antigen, is measured by a blood test and used to determine if prostate cancer is present.

The study included 374 patients with low-risk prostate cancers treated at Fox Chase with either IMRT (216 patients) or I-125 seed brachytherapy (158 patients). Patients who received neoadjuvant hormones were excluded from the study. The IMRT dose ranged from 74 to 78 Gy. The implant dose was 145 Gy. IMRT patients were an average of three years older (median age 67.6 years compared to 64.7 years).

Serious long-term side effects were significantly higher in the I-125 patients, including urethral stricture (narrowing) and catheterization. Catheterization within the first three months was required in three of the IMRT patients and 11 of the I-125 patients. Only one IMRT patient and seven of the implant patients required catheterization more than three months after completing treatment.

"There are limited studies looking at long-term outcomes in IMRT as it is a relatively new technology," said Eade. "However, Fox Chase has been a leader in this area and is one of the only institutions that can investigate this question."

"This study shows men treated with brachytherapy have an increased risk of long-term side effects with brachytherapy as compared to IMRT," Eade said. "Advances in technologies will continue to improve outcomes for both treatment modalities, but for now IMRT delivers excellent cancer control with fewer long-term problems."

Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa. as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu. 


 


Additional Authors:  

Works Cited:  


Article Links:  
 
  • Fox Chase Cancer Center
  •  
     
     
  • CancerNews.com
  •  
     
     
  • Prostate Cancer Information
  •  
     
     
  • CollegeBooks.com - College Textbooks - Medical Textbooks - Nursing Textbooks - College Book Store - Medical Book Store
  •  
     
     
  • Medical News
  •  
     
    ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
     
     

    These review articles are the opinions of the authors. Some of the views may be controversial. CancerNews.com™ does not directly endorse the work. We merely present it as part of our service. Please read the disclaimer.



     
     

    An excellent resource for discount books, textbooks, music and supplies.
    {www.collegebooks.com}
     
     

    Search for great prices on apparel, electronics, sporting goods and more. Buy online and save.
    {www.shoppingnews.com}
     



    This site is property of Net Ventures, Inc.
    Disclaimer/Legal